arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Gain Therapeutics, Inc.

GANX Health Care Biotechnology: Pharmaceutical Preparations
$1.29
▲ +8.4% Today
as of Oct 23, 15:02 ET
Last 30 days -25.29% Sep 14 → Oct 23
$1.13 $1.35 $1.57 $1.79 $2.01 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$1.18
High
$1.33
Low
$1.16
Volume
$3M
Avg Vol
$884,132
Mkt Cap
$75M
P/E (TTM)
—
Beta
—
52w High
$4.34
52w Low
$1.15
Div Yield
—
Shares Out
$43M

Recent Press Releases & News last 60 days · 5 items

Oct 8 · 11:00 PR GlobeNewswire
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
Oct 1 · 13:28 PR GlobeNewswire
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
Sep 29 · 21:50 PR GlobeNewswire
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
▸ Show all 5 press releases & news Free account →

GANX earnings at a glance

The options market is pricing a move of about ±66.7% after the report, a range of roughly $0.43 to $2.15 from today's $1.29. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±1.8% on average; after the most recent report on May 11, 2026 it moved +0.0%. That means options currently expect more movement than GANX has typically delivered. GANX beat the consensus EPS estimate in 0 of its last 4 reported quarters. Implied volatility is currently 6%. The share price of $1.29 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.15
$4.34
4% of range
Avg surprise (last 4)
-2.9%
Avg reaction (last 2)
-1.8%
0% positive
Latest IV / EM
564%
EM ±66.7% · $2 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.62$-0.49$-0.36$-0.24$-0.11 Actual $-0.43Actual $-0.62Actual $-0.37Actual $-0.22Actual $-0.42Actual $-0.17Actual $-0.16Est $-0.16Actual $-0.19Est $-0.17Actual $-0.15Est $-0.15Actual $-0.13Est $-0.13Actual $-0.11 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-6M$-6M$-5M$-5M$-5M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.11 — — — — financials
Mon May 11, 2026Mar/2026 $-0.13 $-0.13 0.0% +18.8% 0.0% earnings
Wed Nov 12, 2025Sep/2025 $-0.15 $-0.15 0.0% — — earnings
Tue Aug 12, 2025Jun/2025 $-0.19 $-0.17 -11.8% — — earnings
Wed May 14, 2025Mar/2025 $-0.16 $-0.16 0.0% — -3.6% earnings
Mon Sep 30, 2024Sep 2024 $-0.17 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.42 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.22 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.37 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.62 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.43 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-5M$-5M—$-5M$-5M$-4M—$-4M
Net income$-5M$-6M—$-5M$-6M$-5M—$-4M
EPS (diluted)$-0.11$-0.13—$-0.15$-0.19$-0.16—$-0.17

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$13M$17M$21M$9M$7M$9M$10M$12M
Inventory————————
Total current assets$15M$18M$22M$11M$9M$11M$12M$14M
Total assets$15M$19M$23M$11M$10M$12M$12M$14M
Long-term debt$220,058$273,265$300,084$298,797$325,359$314,476$328,327$376,130
Total liabilities$4M$5M$4M$5M$6M$6M$5M$5M
Total equity$11M$14M$19M$6M$4M$6M$7M$9M

Implied volatility — last 90 days

39%259%479%700%920% Jun 22 — IV 63% · EM ±13.2%Jun 23 — IV 83% · EM ±17.0%Jun 25 — IV 208% · EM ±40.7%Jun 26 — IV 164% · EM ±31.4%Jun 30 — IV 156% · EM ±26.9%Jul 01 — IV 154% · EM ±25.8%Jul 02 — IV 159% · EM ±25.8%Jul 03 — IV 168% · EM ±26.2%Jul 07 — IV 82% · EM ±10.8%Jul 08 — IV 245% · EM ±30.7%Jul 09 — IV 174% · EM ±20.5%Jul 10 — IV 277% · EM ±30.6%Jul 13 — IV 388% · EM ±32.4%Jul 14 — IV 447% · EM ±32.4%Jul 15 — IV 647% · EM ±38.2%Jul 16 — IV 921% · EM ±38.5%Jul 21 — IV 105% · EM ±24.5%Jul 22 — IV 117% · EM ±26.8%Jul 23 — IV 82% · EM ±18.5%Jul 24 — IV 165% · EM ±36.6%Jul 28 — IV 109% · EM ±22.3%Jul 30 — IV 87% · EM ±17.0%Jul 31 — IV 103% · EM ±19.7%Aug 03 — IV 80% · EM ±14.2%Aug 04 — IV 99% · EM ±17.0%Aug 05 — IV 100% · EM ±16.7%Aug 07 — IV 88% · EM ±13.7%Aug 10 — IV 120% · EM ±16.6%Aug 11 — IV 74% · EM ±9.8%Aug 12 — IV 113% · EM ±14.2%Aug 13 — IV 215% · EM ±25.4%Aug 14 — IV 224% · EM ±24.8%Aug 19 — IV 368% · EM ±21.7%Aug 24 — IV 60% · EM ±12.5%Aug 25 — IV 62% · EM ±12.6%Aug 26 — IV 90% · EM ±18.1%Aug 27 — IV 69% · EM ±13.5%Aug 31 — IV 47% · EM ±8.3%Sep 16 — IV 436% · EM ±25.8%Sep 21 — IV 39% · EM ±8.2%Sep 22 — IV 63% · EM ±12.8%Sep 23 — IV 41% · EM ±8.2%Sep 24 — IV 69% · EM ±13.6%Sep 25 — IV 43% · EM ±8.2%Sep 28 — IV 112% · EM ±19.8%Sep 30 — IV 238% · EM ±39.7%Oct 01 — IV 180% · EM ±29.1%Oct 06 — IV 494% · EM ±65.2%Oct 07 — IV 574% · EM ±71.9%Oct 08 — IV 564% · EM ±66.7%

Sector peers

LFVN
Lifevantage Corporation
$76M $5.71-4.0%
HRTX
Heron Therapeutics, Inc.
$73M $0.30-13.2%
MAIA
MAIA Biotechnology, Inc.
$73M $1.15+0.4%
CTOR
Citius Oncology, Inc.
$71M $0.66-5.6%
TELO
Telomir Pharmaceuticals, Inc.
$80M $0.98-4.4%
CING
Cingulate Inc.
$69M $4.79+2.8%

GANX earnings FAQ

What is GANX's expected move for earnings?

Options currently price a move of about ±66.7%, or $0.86 per share either way from $1.29.

How does GANX stock usually react to earnings?

Across the last 2 reports the average next-day move was ±1.8%, up 0 times and down 2 times.

What is GANX's implied volatility?

GANX's at-the-money implied volatility is about 6% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in